194792-52-4

Upstream product

• 57017-95-5 methyl 3-chloro-4-hydroxyphenylacetate 
• 109-64-8 1,3-dibromo-propane 
• 598-17-4 1,1-dibromopropane 
• 91361-78-3 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester 
• 91373-91-0 (3-chloro-4-dimethylthiocarbamoyloxyphenyl)acetic acid methyl ester 

Downstream Products

• 709028-29-5 (3-Chloro-4-{3-[3-hydroxy-2-propyl-4-(2,2,2-trifluoro-acetyl)-phenoxy]-propylsulfanyl}-phenyl)-acetic acid methyl ester 
• 194608-84-9 methyl 3-chloro-4-(3-(2-propyl-3-hydroxy-4-propionylphenoxy)propylthio)phenylacetate 
• 194855-43-1 methyl 3-chloro-4-(3-(3-ethyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetate 
• 194608-93-0 methyl 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetate 
• 194608-87-2 {3-chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 194608-85-0 {3-Chloro-4-[3-(3-hydroxy-4-{1-[(E)-hydroxyimino]-propyl}-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 194608-89-4 {3-chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 709028-30-8 {3-Chloro-4-[3-(3-hydroxy-2-propyl-4-{2,2,2-trifluoro-1-[(Z)-hydroxyimino]-ethyl}-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 

Relevant academic research and scientific papers

ARYLTHIAZOLIDINEDIONE DERIVATIVES

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR alpha , delta and/or gamma mediated diseases, disorders and conditions.

Phenylacetic acid derivatives as hPPAR agonists

Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. F

Arylthiazolidinedione and aryloxazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or γ mediated diseases, disorders and conditions.

Benzisoxazole-derived antidiabetic compounds

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.

Arylthiazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR α, δ and/or γ mediated diseases, disorders and conditions.

Antidiabetic agents

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.